Abeona Therapeutics (ABEO) Stock Price, Quote & News

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 813 4701

Website: www.abeonatherapeutics.com

Address:

6555 Carnegie Avenue, 4th Floor, Cleveland, United States

alexpitti Dec. 27 at 6:25 PM

who are these ai slop accounts fooling? $ABEO

0 · Reply

SpatialComputingSpark Dec. 27 at 5:35 PM

$ABEO The setup is defined by credibility, not hype; commercial execution has to tighten in upcoming quarters — improving transparency could compress perceived risk. Until validation appears, volatility remains the default.

0 · Reply

hegdaom Dec. 26 at 8:04 PM

$AGIO $ABEO

0 · Reply

VarnishVexillo Dec. 26 at 5:24 PM

$ABEO The environment increasingly favors disciplined operators instead of aggressive storytellers. Balance sheet resilience remains an underappreciated swing factor. Clear execution would attract broader institutional participation. Patience is reasonable — but it must be earned.

1 · Reply

Filvul Dec. 26 at 2:40 PM

$ABEO

0 · Reply

WallStreetBuyDip Dec. 26 at 1:16 PM

$ABEO Trading at $5.41, with highs at $7.23 and lows at $4.17. Average volume stands at 1,168,116, with recent volumes ranging from 709.6k to 1.5M.

0 · Reply

Dkll303 Dec. 26 at 12:36 PM

$ABEO $AGIO as for ABEO , organogenesis out of Mass. , has a skin product on the market and sales SUCK ! just saying

0 · Reply

FitzCatalyst Dec. 26 at 12:15 PM

$ABEO

0 · Reply

1iquid Dec. 26 at 3:10 AM

💎 Liquid® Live Actionable Trade Asset: $ABEO Contracts: $ABEO June 18, 2026 $6 Calls Scale in: $1.89- $2.31 Scale out: $7.35-$12.60 Profit Potential : 173% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

bentley99 Dec. 26 at 2:57 AM

$AGIO $ABEO Both of these for 2026.

0 · Reply

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer

Dec 11, 2025, 7:30 AM EST - 16 days ago

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Dec 8, 2025, 7:30 AM EST - 19 days ago

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy

Dec 1, 2025, 7:30 AM EST - 26 days ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2025, 2:52 PM EST - 6 weeks ago

Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead

Nov 12, 2025, 12:11 PM EST - 6 weeks ago

Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:30 AM EST - 6 weeks ago

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 7 weeks ago

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Oct 30, 2025, 10:45 AM EDT - 2 months ago

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)

Oct 20, 2025, 8:30 AM EDT - 2 months ago

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs

Oct 13, 2025, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program

Oct 8, 2025, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Aug 29, 2025, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 19, 2025, 3:25 PM EDT - 4 months ago

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 4:36 PM EDT - 4 months ago

Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn

Aug 14, 2025, 7:30 AM EDT - 4 months ago

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

Jul 29, 2025, 10:00 AM EDT - 5 months ago

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

Jul 15, 2025, 7:30 AM EDT - 5 months ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

Jul 14, 2025, 7:00 AM EDT - 5 months ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

TECH

Jul 2, 2025, 7:30 AM EDT - 6 months ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Jul 1, 2025, 7:30 AM EDT - 6 months ago

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Jun 30, 2025, 7:30 AM EDT - 6 months ago

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Jun 24, 2025, 7:30 AM EDT - 6 months ago

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Jun 5, 2025, 5:48 AM EDT - 7 months ago

Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)

May 30, 2025, 8:46 AM EDT - 7 months ago

Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference

May 16, 2025, 1:37 AM EDT - 8 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 14, 2025, 8:07 AM EDT - 8 months ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 12, 2025, 7:30 AM EDT - 8 months ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Apr 30, 2025, 4:41 PM EDT - 8 months ago

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Apr 29, 2025, 6:06 AM EDT - 8 months ago

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:00 AM EDT - 8 months ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 27, 2025, 8:30 AM EDT - 8 months ago

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

DDD TKR KARO NNDM ORC PAA PAGP

Apr 21, 2025, 10:00 AM EDT - 8 months ago

Pz-Cel Has Massive Potential For RDEB Patients

Apr 12, 2025, 11:39 AM EDT - 9 months ago

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Mar 20, 2025, 3:20 PM EDT - 10 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:30 AM EDT - 10 months ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 4, 2025, 9:00 AM EST - 10 months ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Jan 24, 2025, 12:40 PM EST - 1 year ago

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 12, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 4, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 3, 2024, 8:09 AM EDT - 1 year ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 12, 2024, 4:59 PM EDT - 1 year ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

alexpitti Dec. 27 at 6:25 PM

who are these ai slop accounts fooling? $ABEO

0 · Reply

SpatialComputingSpark Dec. 27 at 5:35 PM

0 · Reply

hegdaom Dec. 26 at 8:04 PM

$AGIO $ABEO

0 · Reply

VarnishVexillo Dec. 26 at 5:24 PM

1 · Reply

Filvul Dec. 26 at 2:40 PM

$ABEO

0 · Reply

WallStreetBuyDip Dec. 26 at 1:16 PM

$ABEO Trading at $5.41, with highs at $7.23 and lows at $4.17. Average volume stands at 1,168,116, with recent volumes ranging from 709.6k to 1.5M.

0 · Reply

Dkll303 Dec. 26 at 12:36 PM

$ABEO $AGIO as for ABEO , organogenesis out of Mass. , has a skin product on the market and sales SUCK ! just saying

0 · Reply

FitzCatalyst Dec. 26 at 12:15 PM

$ABEO

0 · Reply

1iquid Dec. 26 at 3:10 AM

0 · Reply

bentley99 Dec. 26 at 2:57 AM

$AGIO $ABEO Both of these for 2026.

0 · Reply

Orlandotrader Dec. 25 at 11:25 PM

$ABEO A Weekly close above 5.66 and we are off to the Races

0 · Reply

BillionerOfKing Dec. 25 at 4:22 AM

$ABEO Current Stock Price: $5.42 Contracts to trade: $5 ABEO Jan 16 2026 Call Entry: $0.05 Exit: $0.09 ROI: 79% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Filvul Dec. 24 at 3:16 PM

$ABEO

1 · Reply

FreeWillFinance Dec. 24 at 12:12 PM

$ABEO Risk-adjusted upside exists only if measurable traction replaces episodic catalyst-driven interest. Clear inflection points are required to justify renewed interest.

2 · Reply

commoncentsinvestor Dec. 23 at 3:21 PM

$ABEO Why $ABEO Is Criminally Undervalued at $293M "As 2025 draws to a close, small-cap biotech investors are looking for asymmetric opportunities. We’re looking for stocks with strong cash positions, immune to binary events, approved products finally hitting the market, and valuations that seem to ignore reality. Well I spent most of my downtime this weekend trying to find out everything I could about ABEO -1.48%↓ before allocating 20% of my portfolio into this single stock. I can honestly say that I’ve never felt more comfortable investing into a biotech company." https://aperturebio.substack.com/p/why-abeo-is-criminally-undervalued

0 · Reply

FitzCatalyst Dec. 22 at 7:53 PM

$ABEO 💥

0 · Reply